Gilead’s R&D spending spiked 25% in Q1, shortening investment gap with peers

[{"selector":"#anim-ef4cb6bc-2709-4812-a7ad-5a46888e899a","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9bc29a0c-6324-4a09-a513-5c8e07b00f5c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-fd9533a3-0871-42ae-93ab-1481766c22e2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 1. Gilead has increased its research and development (R&D) spending by 25% in Q1, reaching over $1.4 billion. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-94907abf-c107-4284-a633-e869cd46232b","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 2. Gilead's CFO, Andrew Dickinson, aims for the share of revenue allocated to R&D to be in the low-20% range. Gray Frame Corner Gray Frame Corner

3. Gilead's CFO, Andrew Dickinson, aims for the share of revenue allocated to R&D to be in the low-20% range.

[{"selector":"#anim-30f4ab7a-1f05-4b20-9306-175b5d41150c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-606da340-5005-450d-81a8-e243c6a76e49","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 4. Dickinson expects the company's operating margin to strengthen over time as it progresses through its current phase 3 trials. Gray Frame Corner Gray Frame Corner

5. In 2022, Gilead spent just under $5 billion on R&D, representing roughly 18% of its revenue.

[{"selector":"#anim-97c6ea5b-0dcd-4d6a-86e3-7fdb0c5cde33","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

6. If current spending continues, Gilead could match its peers with a projected R&D budget of $5.8 billion for 2023.

[{"selector":"#anim-24b71aea-34f9-467e-8205-bf8fff294c58","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

7. A significant amount of the R&D budget is being invested in Gilead's existing cell therapy and HIV franchises.

[{"selector":"#anim-32451189-a621-4b9b-900b-e4322bf1f78a","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-064082f7-0133-4d49-bdc3-9db210ded1a4","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 8. The company has also invested in TIGIT, an immuno-oncology target, with more data expected from an ongoing phase 2 trial in the first half of the year. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-f1ead9bb-f4d8-4e12-9e87-96d6fa971fa9","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 9. Gilead reported promising results in December 2022, showing a combination of domvanalimab and Arcus' anti-PD1 zimberelimab reduced the risk of disease progression by 45% compared to zimberelimab alone. Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-a1a94568-3d2a-49f9-a764-8f1fccf9aac7","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 10. More mature data from a larger patient population is expected to be presented later this quarter, according to Gilead's Chief Medical Officer, Merdad Parsey . Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-9fe15eba-15d0-4dba-a6fd-7bcb82e9c7d0","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more